Color Health Partners With Evry Health to Expand Access to Virtual Cancer Care
Color Health is partnering with insurer Evry Health to offer its virtual cancer clinic to employer health plan members.
Color Health is partnering with insurer Evry Health to offer its virtual cancer clinic to employer health plan members.
Obesity and diabetes drug R&D partnerships struck in 2025 represented $20.2 billion in total deal value, a new record high, according to a new report from J.P. Morgan. While IPO activity and venture investment trended downward, M&A activity was significantly higher.
Alan Murray on improving access for medical transportation.
OpenAI announced a new dedicated platform for health conversations. The company said the new offering is not intended for medical diagnosis or treatment — but rather to provide support for personal health navigation.
GSK’s bepirovirsen met the main goal of two Phase 3 studies, achieving functional cure rates for patients with chronic hepatitis B infection after six months of treatment. This antisense oligonucleotide therapy could provide a treatment alternative to antiviral drugs that patients must take for life.
The same forces now at play in medical aesthetics will soon appear in every therapeutic category where treatment overlaps with identity, from hormones to nootropics to genetic optimization.
The weight loss market is at yet another inflection point. The euphoria of the past three years is now confronting the realities of how obesity medications will scale to address an epidemic that impacts over 1 billion people globally.
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Virginia-based health system VHC Health teamed up with virtual physician practice HealthTap to expand access to on-demand care and keep patients within its care network. The collaboration aims to reduce care leakage while offering patients convenient, integrated virtual care backed by VHC’s in-person providers.
Employer-sponsored health insurance costs rose faster than inflation from 2023 to 2024, with higher premiums and deductibles making coverage less affordable for employers and workers, a recent analysis found.
A report supporting the CDC’s revisions says the U.S. is an outlier in the number of diseases and the total number of vaccine doses recommended in its pediatric vaccine schedule. But some physician groups say comparisons to other countries can be misguided and removing vaccines from the schedule puts children’s health at risk.
Moving forward, healthcare providers should expect that personalization is a prerequisite for outstanding patient care. Like in other sectors, it will be a critical component that separates market leaders from those left behind.
The DEA’s anticipated extension of telehealth prescribing flexibility once again averts an immediate disruption in care, but it leaves providers and patients in the same cycle of uncertainty that has persisted for years.
As we see companies release more solutions targeting the revenue cycle, it’s time to distinguish excitement from impact.
The American Medical Association is urging Congress to permanently extend Medicare’s pandemic-era telehealth flexibilities, warning that temporary extensions create uncertainty for patients and providers.
In a sector where delays are measured in lives, early detection, lower attacker dwell time, and system-level misdirection can literally save lives. By marrying preemptive and deceptive technologies, organizations can blunt the attack surface while simultaneously exposing hidden threats before damage is done.
Zenas Biopharma’s obexelimab achieved a statistically significant and clinically meaningful reduction in signs and symptoms of immunoglobulin G4-related disease, but not to the extent shown by Amgen’s Uplizna in its pivotal study. Still, Zenas points to features of its drug that could make it competitive as a maintenance therapy for the rare autoimmune disorder.